Cargando…
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225931/ https://www.ncbi.nlm.nih.gov/pubmed/32260179 http://dx.doi.org/10.3390/cancers12040874 |
_version_ | 1783534168352751616 |
---|---|
author | Facciorusso, Antonio Abd El Aziz, Mohamed A Singh, Siddharth Pusceddu, Sara Milione, Massimo Giacomelli, Luca Sacco, Rodolfo |
author_facet | Facciorusso, Antonio Abd El Aziz, Mohamed A Singh, Siddharth Pusceddu, Sara Milione, Massimo Giacomelli, Luca Sacco, Rodolfo |
author_sort | Facciorusso, Antonio |
collection | PubMed |
description | Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins. |
format | Online Article Text |
id | pubmed-7225931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259312020-05-18 Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis Facciorusso, Antonio Abd El Aziz, Mohamed A Singh, Siddharth Pusceddu, Sara Milione, Massimo Giacomelli, Luca Sacco, Rodolfo Cancers (Basel) Article Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins. MDPI 2020-04-03 /pmc/articles/PMC7225931/ /pubmed/32260179 http://dx.doi.org/10.3390/cancers12040874 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Facciorusso, Antonio Abd El Aziz, Mohamed A Singh, Siddharth Pusceddu, Sara Milione, Massimo Giacomelli, Luca Sacco, Rodolfo Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title_full | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title_fullStr | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title_full_unstemmed | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title_short | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
title_sort | statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225931/ https://www.ncbi.nlm.nih.gov/pubmed/32260179 http://dx.doi.org/10.3390/cancers12040874 |
work_keys_str_mv | AT facciorussoantonio statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT abdelazizmohameda statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT singhsiddharth statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT pusceddusara statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT milionemassimo statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT giacomelliluca statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT saccorodolfo statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis |